(7s)-7-Methyl-1,3,4,6,7,8,9,9a-octahydropyrazino[2,1-c][1,4]oxazine, 98%, 500mg

4-Bromo-2-fluoropyridin-3-ol, 98%, 250mg

2-((TERT-BUTOXYCARBONYL)AMINO)-2-(1-METHYL-1H-PYRAZOL-4-YL)ACETIC ACID, 95.0%, 500mg

(3-Bromo-2-chlorophenyl)boronic acid, 95.0%, 250mg

Chloressigsäureethylester, >=98 %, zur Synthese, 2.5 l, Glasverpackung

1,1,1,2,2,3-Hexafluoro-3-(trifluoromethyl)-5-iodopentane, 97.0%, 1g

N,N'-(Hexane-1,6-diyl)bis(3-phenylprop-2-en-1-imine)>98.0%(HPLC)(T)25g

tert-butyl 4-(anilinocarbonyl)-1,1-dioxidotetrahydro-2H-thiopyran-4-ylcarbamate, 250mg

5-{[(4-methylphenyl)thio]methyl}-2-furoic acid, 95.0%, 250mg

N-(2,6-Dioxopiperidin-3-yl)-2-phenylacetamide, 95.0%, 10mg

2-[[4-[(4-NITROPHENYL)METHOXY]PHENYL]METHYL]-4-THIAZOLIDINECARBOXYLIC ACID ETHYL ESTER, 98%, 5mg

5-Chloro-1H-indole-7-carboxylic acid, 95.0%, 1g

Übergangsstück, Schlaucholive gebogen, mit Hülse NS 29/32, 1 Stück